Alnylam Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference.
CEOYvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees2,230
Employees2,230
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2002
Founded2002
Employees2,230
Employees2,230
ALNY Key Statistics
Market cap61.65B
Market cap61.65B
Price-Earnings ratio-190.62
Price-Earnings ratio-190.62
Dividend yield—
Dividend yield—
Average volume1.14M
Average volume1.14M
High today$485.28
High today$485.28
Low today$467.50
Low today$467.50
Open price$469.19
Open price$469.19
Volume1.44M
Volume1.44M
52 Week high$485.28
52 Week high$485.28
52 Week low$205.87
52 Week low$205.87
ALNY News
Simply Wall St 4d
Alnylam Pharmaceuticals: Valuation Snapshot Following New Phase 3 Data and Pipeline ProgressAlnylam Pharmaceuticals (ALNY) has caught investor attention after announcing progress on two key fronts. The company has initiated the Phase 3 ZENITH study for...
TipRanks 7d
Alnylam and Regeneron Join Forces in Promising Alzheimer’s StudyAlnylam Pharmaceuticals ((ALNY)), Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take...
Analyst ratings
74%
of 31 ratingsBuy
74.2%
Hold
22.6%
Sell
3.2%
People also own
Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.